I det andet aktivt kontrollerede forsøg var andelen af alvorlige bivirkninger efter 2 års behandling den samme i de tre behandlingsgrupper (Enbrel 16, methotrexat 15% og Enbrel i kombination med methotrexat 17%).
In the second active-controlled trial the rate of serious adverse events after 2 years of treatment was similar among the three treatment groups (Enbrell 16%, methotrexate 15% and Enbrel in combination with methotrexate 17%).